Chemokine receptors as biomarkers in multiple sclerosis
Chemokine receptors as biomarkers in multiple sclerosis
复制标题
DOI：
10.1155/2006/694283
复制
发表时间：
2006-01-01
期刊：
影响因子：
--
通讯作者：
Ransohoff, Richard A.
中科院分区：
文献类型：
--
作者：
Fox, Robert J.;Kivisakk, Pia;Ransohoff, Richard A.
白细胞浸润是组织炎症的特征，被认为是多发性硬化症（MS）发病机制中不可或缺的一部分。这一特性强调了理解白细胞迁移机制的重要性。趋化因子是一种分泌的蛋白质，它控制着白细胞向目标器官的运输。趋化因子受体（CKR）在白细胞上的差异表达，其调节是MS疾病修饰治疗的潜在靶点。趋化因子及其受体也是疾病活动性和治疗反应的潜在生物标志物。我们描述了一组MS患者外周血白细胞CKR表达的波动，纵向随访长达36个月。我们观察到，尽管患者之间CKR表达有相当大的差异，但随着时间的推移，每位患者的CKR表达几乎没有波动。这些观察结果表明，每个患者都有一个CKR设定点，而这个设定点因患者而异。评估趋化因子或趋化因子受体作为MS的生物标志物需要考虑CKR表达的个体差异。
Leukocyte infiltrates characterize tissue inflammation and are thought to be integral in the pathogenesis of multiple sclerosis (MS). This attribute underlines the importance of understanding mechanisms of leukocyte migration. Chemokines are secreted proteins which govern leukocyte trafficking into targeted organs. Chemokine receptors (CKR) are differentially expressed on leukocytes and their modulation is a potential target for MS disease modifying therapies. Chemokines and their receptors are also potential biomarkers of both disease activity and response to treatment. We describe the fluctuations in CKR expression on peripheral leukocytes in a group of MS patients followed longitudinally for up to 36 months. We observed little fluctuation in CKR expression within each patient over time, despite considerable variability in CKR expression between patients. These observations suggest that individual patients have a CKR set point, and this set point varies from one patient to another. Evaluation of chemokines or chemokine receptors as biomarkers in MS will need to account for this individual variability in CKR expression.